Dr. Kim on the Role of Biomarker Testing in Treatment Decisions for Solid Tumors

Publication
Video
Supplements and Featured PublicationsOn the Horizon in NSCLC: Antibody Drug Conjugates

Edward S. Kim, MD, MBA, discusses the role of biomarker testing in making treatment decisions for patients with solid tumors.

Edward S. Kim, MD, MBA, physician-in-chief at City of Hope Orange County and vice physician-in-chief at City of Hope National Medical Center, discusses the role of biomarker testing in making treatment decisions for patients with solid tumors.

With the emergence of targeted therapies and different agents for the treatment of various malignancies, biomarker testing has become an essential part of the diagnosis of a patient, Kim says. Although radiologic tests, pathology, and histology information are available, the full scope of the patient’s disease is not complete without biomarker testing, Kim stresses.

Despite the importance of biomarker testing, rates of testing remain significantly short of where they should be, Kim continues, adding that mutations or other biomarkers can influence treatment decisions. Biomarker testing can identify patients who may be candidates for a specific therapy that can improve their outcome or deliver similar efficacy with a better safety profile, Kim concludes.

Related Videos
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Gautam Jha, MD, medical director, M Health Fairview Masonic Cancer Clinic and the Advanced Treatment Center at the M Health Fairview Clinics and Surgery Center—Minneapolis, chair, cancer committee, M Health Fairview Ridges Hospital
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute